EUVIMEDSkopri EUVIMED
EditorialKommentar

Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis

Giovanni Targher iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17747 ↗

At a glance

Editorial in Alimentary Pharmacology & Therapeutics, 2024. Written by Giovanni Targher. Institution: Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Pyridazines. Cited 5 times so far (Crossref); 9 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

LINKED CONTENT This article is linked to Harrison et al paper. To view this article, visit https://doi.org/10.1111/apt.17734

Subjects

MeSH terms (MEDLINE)

Non-alcoholic Fatty Liver DiseasePyridazinesHumansLiver CirrhosisUracil

Substances

resmetiromPyridazinesUracil

Authors and institutions

  • Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy.
  • Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy.

ORCID profiles: Giovanni Targher

Cite

APA

Targher, G. (2024). Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17747

Vancouver

Targher G. Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17747

BibTeX
@article{Targher2024,
  author = {Targher, Giovanni},
  title = {Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17747}
}
Start for free →